A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Recruiting · Phase 3 · NCT06963827
Conditions: Kidney Disease
At a glance
- Research payments reported, 2025
- $416,448
- U.S. investigators named
- 16
- Sites paid
- 12
- Planned or actual enrollment
- 347
About the trial
- Sponsor
- Takeda
- Tested
- Mezagitamab (drug), Placebo (drug)
- Dates
- Started 2025-07-15; completion 2030-01-14
- Results posted
- Not yet
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find …
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $416,448 in research payments for this study in 2025 (66 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mohamed A. El-shahawy, M.D. Nephrology (Kidney) · Los Angeles, CA
- Max F. Benjamin, M.D Specialist · Pembroke Pines, FL
- Jose M. Cardona-guzman, MD Nephrology (Kidney) · Miami, FL
- Arvind Madan, MD Nephrology (Kidney) · Orlando, FL
- Edouard R. Martin, M.D. Nephrology (Kidney) · Lauderdale Lakes, FL
- Vinayak Ramanath, MD Nephrology (Kidney) · Lagrange, GA
- Tamorie Smith, MD Nephrology (Kidney) · Columbus, GA
- Arnold Silva, MD, PHD Nephrology (Kidney) · Meridian, ID
- Marwan Kaskas, MD Nephrology (Kidney) · Shreveport, LA
- Shannon E. Doyle, MD. Internal Medicine · Maplewood, MN
- Ahmed M. Awad, DO Nephrology (Kidney) · Kansas City, MO
- Xiaoying Deng, MD Nephrology (Kidney) · Fargo, ND
- Syed A. Hussain, MD Nephrology (Kidney) · Katy, TX
- Sreedhar A. Mandayam, M.D. Nephrology (Kidney) · Houston, TX
- Leonel Reyes, M.D. Family Medicine · San Antonio, TX
- Simon S. Rodriguez, M.D. Nephrology (Kidney) · El Paso, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Davita Clinical Research $119,614
- Bioresearch PArtner Holdings Lllp $77,272
- Provecta Research Network LLC $33,953
- Thomas Jefferson University Hospital, PA $28,200
- Sun Research Institute $28,175
- Ctr Oakwater LLC $27,709
- South Florida Research Institute $21,800
- Care Institute LLC $20,100
- Academic Medical Research Institute $19,025
- Northwest Louisana Nephrology $17,800
- R and H Clinical Research Inc $12,800
- Johnson County Clintrials $10,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.